Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.72 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4442122 | 0.98 | CYP17A1 (0.70) | CYP17A1MKNK1MKNK2CHEK2HDAC1 | |
| SCHEMBL8582840 | 0.85 | NAPRT (0.59) | CYP17A1MKNK1MKNK2CHEK2CDC7 | |
| SCHEMBL44995 | 0.85 | — | — | |
| SCHEMBL1002578 | 0.85 | CA2 (0.67) | CYP17A1MKNK1MKNK2MAP4K4CA12 | |
| SCHEMBL22284875 | 0.85 | CYP17A1 (1.00) | CYP17A1MKNK1MKNK2CHEK2HDAC1 | |
| Hydrochloric Acid SCHEMBL5710616 | 0.83 | CYP17A1 (0.57) | CYP17A1MKNK1MKNK2CHEK2CDC7 | |
| Water SCHEMBL31094001 | 0.83 | CYP17A1 (0.57) | CYP17A1MKNK1MKNK2CHEK2CDC7 | |
| SCHEMBL28382890 | 0.83 | CYP17A1 (0.57) | CYP17A1MKNK1MKNK2CHEK2CDC7 | |
| Hydrochloric Acid SCHEMBL1666770 | 0.83 | CYP17A1 (0.57) | CYP17A1MKNK1MKNK2CHEK2CDC7 | |
| Hydrochloric Acid SCHEMBL28802361 | 0.83 | CYP17A1 (0.57) | CYP17A1MKNK1MKNK2CHEK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | claimed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | claimed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | claimed |
| EP-0999834-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-10-12 | — | — | EP | claimed |
| US-6586459-B2 | Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide | BEIGHT DOUGLAS WADE (US) | 2003-07-01 | — | — | US | claimed |
| US-6583173-B2 | Useful as anticoagulants in mammals; inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-06-24 | — | — | US | claimed |
| US-20020072531-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-06-13 | — | — | US | claimed |
| US-20020049234-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-04-25 | — | — | US | claimed |
| JP-2002506462-A | — | — | 2002-02-26 | — | — | JP | claimed |
| US-6313151-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | claimed |
| EP-0999834-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-04-04 | — | — | EP | claimed |
| EP-0999834-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999000126-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | claimed |
| CN-1073430-A | Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1993-06-23 | — | — | CN | claimed |
| EP-3784226-B1 | PYRAZOLE-PHENYLAMIDE DERIVATIVES AS INHIBITORS OF THE RHO-ASSOCIATED PROTEIN KINASE ROCK1 AND ROCK2 FOR THE TREATMENT OF CANCER | TRANSLATIONAL DRUG DEV LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| WO-1999000126-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
| CN-1073430-A | Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1993-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | CYP17A1 1379/4885MKNK1 243/4885MKNK2 485/4885 |
| US-20020072531-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | CYP17A1 504/4885MKNK1 3797/4885MKNK2 3548/4885 |
| US-20020049234-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | CYP17A1 504/4885MKNK1 3797/4885MKNK2 3548/4885 |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | CYP17A1 1529/4885MKNK1 4139/4885MKNK2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.